Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose significant issues affecting its sales and financial guidance during the specified class period [1][2][3]. Summary by Sections Class Action Lawsuit - The lawsuit is on behalf of all individuals and entities who purchased RxSight securities between November 7, 2024, and July 8, 2025, with a deadline of September 22, 2025, for investors to apply as lead plaintiffs [1]. - Allegations include that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization, and that the demand for its products was overstated [2]. Financial Performance - On July 8, 2025, RxSight reported preliminary second-quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [3]. - The company lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint, attributing the decline to adoption challenges [3]. - Following this announcement, RxSight's stock price fell nearly 38% [3].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

Investors can contact the law firm at no cost to learn more about recovering their losses​ LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. RxSight investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Les ...

NEW YORK, July 23, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025.So What: If you purchased RxSight securities during the Class Period you m ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against RxSight, Inc. for allegedly overstating product demand and failing to disclose sales declines due to adoption challenges and structural issues [1][2]. Group 1 - The lawsuit represents investors who purchased or acquired RxSight's securities between November 7, 2024, and July 8, 2025 [1]. - Defendants are accused of not disclosing significant challenges that affected the company's sales performance [2]. - The deadline to file as a lead plaintiff in the class action is September 22, 2025 [3]. Group 2 - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 [4].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) [2]. Financial Performance - The company previously reported strong sales for LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing market softening, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [4]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [5].

Core Viewpoint - The Schall Law Firm is investigating claims against RxSight, Inc. for potential violations of securities laws following a significant decline in the company's stock price after disappointing financial results [1][2]. Financial Performance - RxSight reported a decline in sales of Light Delivery Devices (LDD) and light adjustable intraocular lenses (LAL), contributing to an overall revenue decrease [2]. - The company lowered its full-year guidance for 2025, citing "Adoption challenges over the last few quarters" as a primary reason for the stall in LDD sales [2]. - Following the announcement of these results on July 9, 2025, RxSight's shares fell by 37.8% [2]. Legal Investigation - The investigation by the Schall Law Firm focuses on whether RxSight made false or misleading statements or failed to disclose important information to investors [2].

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight specializes in manufacturing and selling light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for its LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 per share [4]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization, resulting in another 38% decline in stock price from $12.79 to $7.95 per share [5].

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [4]. - A further revenue forecast cut on July 8, 2025, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [5].